List of Excipients in Branded Drug VINBLASTINE SULFATE

Generic Drugs Containing VINBLASTINE SULFATE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	vinblastine sulfate	63323-278	BENZYL ALCOHOL
Fresenius Kabi USA LLC	vinblastine sulfate	63323-278	SODIUM CHLORIDE
Fresenius Kabi USA LLC	vinblastine sulfate	63323-278	WATER

What are the Most Frequently-Used Excipients in VINBLASTINE SULFATE?

# Of NDCs	Excipient
1	BENZYL ALCOHOL
1	SODIUM CHLORIDE
1	WATER

Last updated: August 11, 2026

ecutive summary: Vinblastine sulfate is a mature, generic injectable oncology product with limited composition-of-matter patent value and no biosimilar pathway. Commercial differentiation depends on excipient control, sterile manufacturing, container-closure performance, ready-to-use presentation, supply reliability, and pharmacy safety. The core formulation is a preservative-free aqueous solution containing vinblastine sulfate, sodium chloride, and water for injection, with pH adjustment as needed. The strongest opportunities are improved handling formats, validated stability, reduced preparation steps, and dependable global supply rather than new active-ingredient exclusivity.

Vinblastine Sulfate Excipient Strategy and Commercial Opportunities

What is the current formulation of vinblastine sulfate injection?

Vinblastine sulfate is administered intravenously for malignancies including Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer, breast cancer, and other cancers. It is a vinca alkaloid and a vesicant. Intrathecal administration is fatal and prohibited in product labeling.[1]

Commercial injectable products generally use a simple aqueous formulation:

Formulation element	Typical role
Vinblastine sulfate	Active pharmaceutical ingredient
Sodium chloride	Isotonicity adjustment
Water for injection	Sterile vehicle
Hydrochloric acid, sulfuric acid, sodium hydroxide, or equivalent	pH adjustment, depending on manufacturer
Preservative	Generally absent in single-dose presentations

U.S. labels commonly describe vinblastine sulfate injection at a concentration equivalent to 1 mg/mL of vinblastine. Products may be supplied in vials or other sterile presentations, and the exact excipient list, fill volume, overfill, pH range, and container closure must be confirmed against the individual manufacturer’s FDA labeling.[1,2]

The formulation is commercially mature. A complex excipient system is not required to solubilize the drug because vinblastine sulfate is a water-soluble salt. The technical challenge is maintaining potency, sterility, particulate control, container compatibility, and safe administration over the labeled shelf life.

What excipients are most important for vinblastine sulfate?

Sodium chloride and tonicity control

Sodium chloride is the principal functional excipient in many injectable presentations. It helps produce an administration-compatible solution and supports dilution into standard intravenous fluids.

A developer should avoid unnecessary ionic complexity. Additional buffers, chelators, antioxidants, or surfactants can create new extractables, compatibility, toxicology, and regulatory burdens without clear clinical benefit.

pH adjustment agents

Vinblastine sulfate solutions require controlled pH. The selected acid or base affects chemical stability, compatibility with the vial and stopper, and the risk of precipitation after dilution.

A narrow, justified pH specification is preferable to an unnecessarily broad range. The development package should connect pH limits to:

• Assay and related-substance stability
• Visible and subvisible particles
• Container-closure compatibility
• Dilution performance in 0.9% sodium chloride or other labeled diluents
• Freeze-thaw and temperature-excursion behavior

Water for injection

Water for injection is the primary vehicle. The product requires validated control of bioburden, endotoxin, particulate matter, and sterilization or aseptic-processing parameters.

Preservatives

Preservatives may create additional toxicity and compatibility concerns in oncology injectables. A preservative-free, single-dose design is generally the lowest-risk commercial configuration where manufacturing economics support it.

A multidose format could reduce packaging cost per milligram but would create a more demanding microbial-control and in-use stability program. For a vesicant used in controlled clinical settings, the safety and workflow advantages of single-dose packaging generally outweigh the theoretical benefit of multidose economics.

What formulation patents protect vinblastine sulfate?

The original composition-of-matter and early product protection for vinblastine sulfate are long expired. Vinblastine is a legacy small-molecule cytotoxic agent, not a recently developed pharmaceutical with an active primary patent estate.

Protection category	Commercial assessment
Composition-of-matter patents	Expired or commercially irrelevant
Original formulation patents	Expected to be expired
Method-of-use patents	Possible only for narrow, later-developed uses; unlikely to block the core generic product
Manufacturing patents	Potentially relevant if a supplier claims a novel semisynthesis, purification, crystallization, or impurity-control process
Device or packaging patents	Possible for specialized administration systems, premixed bags, or safety-transfer components
FDA Orange Book patents	Must be checked by product and NDA; old vinblastine products generally present limited listed-patent risk
Biosimilar exclusivity	Not applicable because vinblastine sulfate is a small molecule

The principal intellectual-property opportunity is therefore not a new vinblastine molecule. It is a defensible formulation, packaging, manufacturing, or delivery improvement with a clinically meaningful operational advantage.

What is the FDA regulatory status of vinblastine sulfate?

Vinblastine sulfate is regulated as an injectable prescription drug. Generic applicants generally pursue an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act when a suitable reference product and product-specific guidance support the pathway.[3]

Key regulatory requirements include:

• Pharmaceutical equivalence to the reference product
• Equivalent strength and dosage form
• Sterility and bacterial endotoxin control
• Injectable particulate limits
• Stability through the proposed shelf life
• Container-closure integrity
• Compatibility with labeled diluents and infusion systems
• Safe labeling for vesicant handling and intravenous-only administration
• Demonstration that proposed excipients are appropriate for the route and concentration

FDA product-specific guidance should be reviewed before selecting a nontraditional excipient system or a materially different presentation. A formulation that is clinically reasonable may still create an equivalence or labeling problem if it departs from the reference product without a clear regulatory basis.

What is the Orange Book status of vinblastine sulfate?

The Orange Book status is product-specific and can change as reference products, discontinued products, and generic approvals are updated. Vinblastine sulfate is primarily a generic-competition product rather than a branded product with meaningful remaining market exclusivity.[4]

An applicant should review:

1. The active reference listed drug.
2. The currently marketed strength and presentation.
3. Any listed patents or pediatric exclusivity.
4. Therapeutic-equivalence codes for approved products.
5. Discontinued-product determinations.
6. Manufacturer-specific labeling and excipient differences.

For a mature injectable, the commercial risk is less likely to arise from a Paragraph IV patent challenge than from product-specific regulatory delays, sterile-manufacturing deficiencies, supply interruptions, or inability to secure a reliable active-ingredient source.

When does vinblastine sulfate lose exclusivity?

The principal exclusivity periods for vinblastine sulfate have already expired. There is no practical remaining small-molecule exclusivity barrier comparable to the 5-year new chemical entity period for a modern branded oncology drug.

Exclusivity type	Vinblastine sulfate assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	No general current barrier for the core product
Pediatric exclusivity	No meaningful current commercial barrier expected
Patent term extension	Not relevant to the mature generic market
Biosimilar interchangeability exclusivity	Not applicable
Generic 180-day exclusivity	Could apply to a specific first-filer under ANDA rules, but would be applicant-specific and time-limited

Generic launch timing depends on ANDA review, facility readiness, inspection outcomes, drug-substance supply, and market conditions. A first filer could receive a temporary competitive advantage, but it would not create durable product exclusivity.

What excipient strategy is strongest for a new vinblastine sulfate product?

Strategy 1: Reference-like aqueous solution

The lowest regulatory-risk route is a simple solution using the established excipient architecture. This approach minimizes:

• New excipient justification
• Bioequivalence complexity
• Toxicology requirements
• Compatibility risks
• Labeling divergence
• Manufacturing development time

The principal disadvantage is limited differentiation. Price and supply reliability become the main competitive variables.

Strategy 2: Ready-to-use vial

A ready-to-use vial can reduce pharmacy compounding steps and lower exposure risk during preparation. The commercial case is strongest when the product has:

• A stable, single-dose presentation
• Clear concentration labeling
• Low withdrawal loss
• Compatible syringe and transfer-device performance
• Tamper-evident packaging
• Barcoded unit-dose identification

The product must remain compatible with institutional hazardous-drug procedures. Packaging cannot imply that a vesicant is safe to handle without appropriate controls.

Strategy 3: Premixed infusion bag

A premixed bag could offer greater workflow value than a vial because it eliminates a dilution step. The barriers are higher:

• Larger fill volume and packaging surface area
• Greater adsorption and leachables exposure
• More complex container-closure validation
• Longer stability assessment after preparation
• Shipping and storage constraints
• Potentially higher wastage when patient doses are individualized

A premixed format is more attractive for common fixed doses or high-volume hospital protocols. It is less attractive where dosing is highly individualized and vial-based preparation already fits institutional practice.

Strategy 4: Enhanced low-temperature or excursion stability

Improved stability under refrigerated, room-temperature, or transport-excursion conditions could support global distribution and reduce hospital wastage. This opportunity requires evidence that the improvement is real and clinically useful, not merely a wider theoretical storage range.

The development program should assess assay, degradation products, color, particles, pH, sterility, endotoxin, and container closure across intended storage conditions.

What manufacturing and excipient barriers affect vinblastine sulfate?

Active-ingredient supply

Vinblastine is a complex natural-product-derived alkaloid. The drug substance is associated with specialized extraction, purification, and chemical-processing capabilities. A formulation company that controls only the finished dosage form remains exposed to:

• Limited qualified API suppliers
• Agricultural or botanical supply variability
• Long lead times
• Impurity-profile changes
• Regulatory changes at the API facility
• Geopolitical concentration in supply chains

Dual sourcing and a detailed impurity-control strategy are commercially important.

Sterile manufacturing

The finished product requires validated aseptic or terminal-sterilization controls appropriate to the formulation and container. A simple formulation does not mean a simple product. Oncology injectables face high expectations for:

• Visible and subvisible particulate control
• Container-closure integrity
• Low bioburden
• Operator protection
• Cross-contamination prevention
• Cleaning validation
• Potent-compound containment

A manufacturer may need dedicated areas or validated campaign controls for cytotoxic materials.

Container and administration compatibility

Vinblastine may interact with container materials, elastomer closures, filters, syringes, and infusion tubing. The development plan should test the complete system rather than the vial alone.

Important variables include:

• Glass type and surface treatment
• Stopper composition
• Silicone oil
• Adsorption to polymeric components
• Light exposure
• Filter compatibility
• Diluent concentration
• Contact time before administration
• Temperature during transport and preparation

These studies can generate practical product differentiation and, where genuinely novel, potential formulation or packaging patent claims.

Which companies are challenging vinblastine sulfate?

The market is generally populated by generic injectable manufacturers rather than companies pursuing branded patent challenges. Manufacturers may include specialty injectable companies, large generic pharmaceutical companies, and contract manufacturers. Product availability varies by country and over time.

Public FDA labeling and approval databases should be used to identify current applicants, holders, strengths, and presentations. A conventional Paragraph IV campaign is unlikely to be the central competitive issue because the product is already mature and broadly genericized. The more relevant competitors are manufacturers that can maintain supply, pass inspections, and offer hospital-friendly packaging.

What generic launch risks exist for vinblastine sulfate?

Low patent risk, high execution risk

The generic entry profile is unusual:

Risk category	Relative importance
Active patent blocking	Low
Biosimilar competition	None
ANDA formulation equivalence	Moderate
Sterile manufacturing	High
API continuity	High
Hospital contracting	High
Product shortage risk	High
Price erosion	High
Differentiated packaging opportunity	Moderate

A new entrant may obtain approval yet fail commercially if it cannot supply consistently or compete in hospital tenders. Injectable oncology markets can have fewer reliable suppliers than the number of approved products suggests.

How strong is the patent estate for a new vinblastine formulation?

A new patent position would be strongest when it claims a specific, reproducible technical solution tied to measurable performance. Potential claim areas include:

• A defined pH and excipient ratio that improves stability
• A low-surface-binding container system
• A premixed infusion formulation with extended in-use stability
• A specific lyophilized composition, if technically justified
• A validated packaging configuration that reduces particulate generation
• A manufacturing process that controls a critical impurity
• A closed transfer system designed for vinblastine administration

Weak claims would cover routine use of sodium chloride, water for injection, standard pH adjustment, or conventional vial packaging without an unexpected technical effect.

A formulation patent would not automatically prevent sale of a reference-like generic product. Its value would depend on claim scope, enablement, freedom-to-operate analysis, and whether hospitals value the protected presentation enough to support a price premium.

What licensing deals and commercial partnerships are relevant?

There is no obvious need for a branded licensing deal around the core vinblastine molecule. Commercial partnerships are more likely to involve:

• API supply and second-source qualification
• Contract sterile filling
• Regional marketing rights
• Hospital group purchasing access
• Premixed chemotherapy distribution
• Hazardous-drug handling systems
• Specialty pharmacy or oncology-clinic distribution

The most valuable partnership would combine a qualified cytotoxic API source with a sterile manufacturing network and hospital contracting capability. A formulation owner without supply-chain control may have limited bargaining power because the active product is substitutable.

How does vinblastine sulfate compare with other vinca alkaloids?

Product	Dosage form	Main commercial distinction
Vinblastine sulfate	Intravenous injection	Mature generic, vesicant, individualized oncology dosing
Vincristine sulfate	Intravenous injection	Strong medication-safety controls; similarly mature generic market
Vinorelbine tartrate	Intravenous and oral products in some markets	Broader presentation potential and different clinical positioning
Eribulin mesylate	Intravenous injection	Newer branded/generic dynamics and different patent history

Vinblastine has fewer obvious delivery opportunities than oral or depot oncology products because it is administered intravenously and requires cytotoxic handling. Its commercial advantage is established clinical use, not formulation novelty.

Key Takeaways

• Vinblastine sulfate is a mature generic injectable with no meaningful remaining core-molecule exclusivity.
• The standard formulation is a simple sterile aqueous solution, commonly using sodium chloride and water for injection with pH adjustment.
• Preservative-free single-dose packaging is generally the lowest-risk formulation strategy.
• Ready-to-use vials and premixed infusion bags offer the clearest commercial differentiation.
• A premixed bag could reduce pharmacy preparation, but it creates higher stability, packaging, and wastage risks.
• The most important barriers are sterile manufacturing, API continuity, particulate control, and hospital procurement.
• Biosimilar risk is not relevant because vinblastine sulfate is a small molecule.
• Paragraph IV litigation is less important than ANDA execution and supply reliability.
• New patent value is most likely in formulation, container compatibility, manufacturing, or closed-transfer systems.
• The strongest commercial model combines a reference-like formulation with reliable supply and workflow-focused packaging.

FAQs About Vinblastine Sulfate Formulation and Commercial Strategy

Is vinblastine sulfate supplied as a lyophilized powder?

Some injectable oncology products use lyophilization, but vinblastine sulfate is commonly marketed as an aqueous solution. A lyophilized product would need to justify the added manufacturing cost through improved stability, transport, or supply economics.

Can vinblastine sulfate be formulated with a preservative?

A preservative may be technically possible, but it would require specific safety, compatibility, antimicrobial-effectiveness, and regulatory justification. A preservative-free single-dose product is generally more straightforward.

Can vinblastine sulfate be administered subcutaneously?

The labeled route is intravenous administration. It is a vesicant, and extravasation can cause severe tissue injury. A new nonintravenous route would require a separate development and regulatory strategy.

Is a vinblastine sulfate premix eligible for a 505(b)(2) application?

A premixed product could potentially raise 505(b)(2) questions if it differs materially from an approved product and relies partly on FDA findings for the reference product. The appropriate pathway depends on the formulation, presentation, labeling, and extent of reliance.

What is the main investment thesis for a vinblastine sulfate product?

The strongest thesis is supply-chain and workflow differentiation, not molecule-level exclusivity. A manufacturer with qualified API sources, reliable sterile capacity, hospital contracts, and a low-waste ready-to-use presentation could compete in a mature but operationally constrained market.

References

1. DailyMed. (n.d.). Vinblastine sulfate injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. Pfizer Inc. (n.d.). Velban (vinblastine sulfate) injection prescribing information. U.S. Food and Drug Administration labeling archives.

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/ index.cfm

5. National Cancer Institute. (n.d.). Vinblastine sulfate. https://www.cancer.gov/ about-cancer/treatment/drugs/vinblastine-sulfate